HUP9900799A2 - Eljárás lantán-karbonát-hidrátok előállítására és az azokat tartalmazó gyógyászati készítmények - Google Patents
Eljárás lantán-karbonát-hidrátok előállítására és az azokat tartalmazó gyógyászati készítményekInfo
- Publication number
- HUP9900799A2 HUP9900799A2 HU9900799A HUP9900799A HUP9900799A2 HU P9900799 A2 HUP9900799 A2 HU P9900799A2 HU 9900799 A HU9900799 A HU 9900799A HU P9900799 A HUP9900799 A HU P9900799A HU P9900799 A2 HUP9900799 A2 HU P9900799A2
- Authority
- HU
- Hungary
- Prior art keywords
- lanthanum
- lanthanum carbonate
- carbonate
- hydrated
- pharmaceutical composition
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- AFCUGQOTNCVYSW-UHFFFAOYSA-H lanthanum(3+);tricarbonate;hydrate Chemical class O.[La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O AFCUGQOTNCVYSW-UHFFFAOYSA-H 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229910017569 La2(CO3)3 Inorganic materials 0.000 abstract 5
- NZPIUJUFIFZSPW-UHFFFAOYSA-H lanthanum carbonate Chemical compound [La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O NZPIUJUFIFZSPW-UHFFFAOYSA-H 0.000 abstract 4
- 229960001633 lanthanum carbonate Drugs 0.000 abstract 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 2
- 239000013078 crystal Substances 0.000 abstract 2
- 229910052746 lanthanum Inorganic materials 0.000 abstract 2
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 abstract 2
- MRELNEQAGSRDBK-UHFFFAOYSA-N lanthanum(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[La+3].[La+3] MRELNEQAGSRDBK-UHFFFAOYSA-N 0.000 abstract 2
- GAYSPCNXZCAPHX-UHFFFAOYSA-H lanthanum(3+);tricarbonate;octahydrate Chemical compound O.O.O.O.O.O.O.O.[La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O GAYSPCNXZCAPHX-UHFFFAOYSA-H 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 abstract 1
- 150000008041 alkali metal carbonates Chemical class 0.000 abstract 1
- 235000013877 carbamide Nutrition 0.000 abstract 1
- 239000004202 carbamide Substances 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 150000002603 lanthanum Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910009112 xH2O Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/244—Lanthanides; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01F—COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS
- C01F17/00—Compounds of rare earth metals
- C01F17/20—Compounds containing only rare earth metals as the metal element
- C01F17/247—Carbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/70—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
- C01P2002/72—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by d-values or two theta-values, e.g. as X-ray diagram
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Geology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Meghatárőzőtt mennyiségű kristályvizet tartalmazó, La2(CO3)3.xH2Oáltalánős képletű, hidratált lantán-karbőnát, ahől a fenti általánősképletben x értéke 3 és 6 között, és előnyösen 3,8 és 4,5 között van. Atalálmány tárgyát képezik tővábbá az említett, hidratált lantán-karbőnátőt tartalmazó gyógyászati készítmények, tővábbá eljárás azemlített, hidratált lantán-karbőnát előállítására. Az említett,hidratált lantán-karbőnátőt a találmány értelmében úgy állítják elő,hőgy a) lantán-őxidőt egy őlyan savval reagáltatnak, amely a lantán őldhatósóját szőlgáltatja; b) az így kapőtt lantán-só őldatát egy alkálifém-karbőnáttalreagáltatják, és így nedves, kiszűrt főrmában lantán-karbőnát-őktahidrátőt állítanak elő; és c) a nedves, kiszűrt lantán-karbőnát-őktahidrátőt szabályőzőtt módőnszárítva 3-6 mől kristályvizet tartalmazó lantán-karbőnátőt állítanakelő. ŕ
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9506126.3A GB9506126D0 (en) | 1995-03-25 | 1995-03-25 | Pharmaceutical composition and method |
PCT/GB1996/000575 WO1996030029A1 (en) | 1995-03-25 | 1996-03-19 | Pharmaceutical composition containing selected lanthanum carbonate hydrates |
Publications (3)
Publication Number | Publication Date |
---|---|
HUP9900799A2 true HUP9900799A2 (hu) | 1999-09-28 |
HUP9900799A3 HUP9900799A3 (en) | 2000-10-30 |
HU224198B1 HU224198B1 (hu) | 2005-06-28 |
Family
ID=10771896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU9900799A HU224198B1 (hu) | 1995-03-25 | 1996-03-19 | Lantán-karbonát-hidrátokat tartalmazó gyógyászati készítmények hiperfoszfatémia kezelésére és eljárás előállításukra |
Country Status (28)
Country | Link |
---|---|
US (1) | US5968976A (hu) |
EP (1) | EP0817639B1 (hu) |
JP (1) | JP3224544B2 (hu) |
KR (1) | KR100329340B1 (hu) |
CN (1) | CN1102393C (hu) |
AT (1) | ATE209923T1 (hu) |
AU (1) | AU702073B2 (hu) |
BR (1) | BR9607926A (hu) |
CA (1) | CA2216437C (hu) |
CZ (1) | CZ293494B6 (hu) |
DE (4) | DE69617659D1 (hu) |
DK (1) | DK0817639T3 (hu) |
EA (1) | EA000270B1 (hu) |
EE (1) | EE04096B1 (hu) |
ES (1) | ES2170223T3 (hu) |
GB (1) | GB9506126D0 (hu) |
HK (1) | HK1008182A1 (hu) |
HU (1) | HU224198B1 (hu) |
MX (1) | MX9707334A (hu) |
NO (1) | NO313488B1 (hu) |
NZ (1) | NZ303260A (hu) |
PL (1) | PL184315B1 (hu) |
PT (1) | PT817639E (hu) |
SK (1) | SK282607B6 (hu) |
TR (1) | TR199701030T1 (hu) |
TW (1) | TW436288B (hu) |
WO (1) | WO1996030029A1 (hu) |
ZA (1) | ZA962369B (hu) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9720061D0 (en) * | 1997-09-19 | 1997-11-19 | Crosfield Joseph & Sons | Metal compounds as phosphate binders |
GB0015745D0 (en) * | 2000-06-27 | 2000-08-16 | Shire Holdings Ag | Treatment of bone diseases |
DE60239329D1 (de) | 2001-04-23 | 2011-04-14 | Shire Int Licensing Bv | Verwendung von lanthankarbonat zur prävention von nierensteinleiden |
AU2003229437A1 (en) * | 2002-05-08 | 2003-11-11 | Shire Holding Ag | Use of lanthanum for the treatment of hypercalcemia and bone metastasis |
US20040161474A1 (en) * | 2002-05-24 | 2004-08-19 | Moerck Rudi E. | Rare earth metal compounds methods of making, and methods of using the same |
US20060083791A1 (en) | 2002-05-24 | 2006-04-20 | Moerck Rudi E | Rare earth metal compounds methods of making, and methods of using the same |
CN100526219C (zh) * | 2002-08-14 | 2009-08-12 | 爱尔达纳米公司 | 稀土金属化合物、其制造方法及其使用方法 |
EP1647524A3 (en) * | 2002-08-14 | 2006-09-13 | Altair Nanomaterials Inc. | Rare earth metal compounds, methods of making, and methods of using the same |
US7381428B2 (en) * | 2003-08-26 | 2008-06-03 | Shire International Licensing B.V. | Stabilized lanthanum carbonate compositions |
CA2536959C (en) * | 2003-08-26 | 2011-08-02 | Shire Holdings Ag | Pharmaceutical formulation comprising lanthanum compounds |
EP1708723A4 (en) * | 2004-07-27 | 2006-12-20 | Shire Pharmaceuticals Inc | METHOD FOR TREATING HYPERPHOSPHATEMIA USING LANTHAN HYDROXYCARBONATE |
US7700608B2 (en) * | 2004-08-04 | 2010-04-20 | Shire Holdings Ag | Quinazoline derivatives and their use in the treatment of thrombocythemia |
JP2008516971A (ja) * | 2004-10-15 | 2008-05-22 | アルテアーナノ,インコーポレーテッド | 錠剤による負荷が軽減されるリン酸塩結合剤 |
ITME20040015A1 (it) * | 2004-12-07 | 2005-03-07 | Vincenzo Savica | Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico. |
GB0502787D0 (en) * | 2005-02-10 | 2005-03-16 | Ineos Silicas Ltd | Pharmaceuticlly active compounds, their manufacture, compositions containing them and their use |
EP1698233A1 (en) * | 2005-03-01 | 2006-09-06 | Bayer HealthCare AG | Reduction of digestibility of phosphorus in animal nutrition |
JP2009504781A (ja) * | 2005-08-17 | 2009-02-05 | アルテアナノ インコーポレイテッド | 家畜における高リン血症:治療のための組成物、及び治療方法 |
CA2619643A1 (en) * | 2005-08-17 | 2007-02-22 | Altairnano, Inc. | Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods |
US20070104799A1 (en) * | 2005-11-09 | 2007-05-10 | Shire International Licensing B.V. | Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds |
MY157620A (en) | 2006-01-31 | 2016-06-30 | Cytochroma Dev Inc | A granular material of a solid water-soluble mixed metal compound capable of binding phosphate |
CN100398112C (zh) * | 2006-03-24 | 2008-07-02 | 辽宁诺康生物制药有限责任公司 | 一种治疗血磷酸盐过多症的药物及其制备方法 |
US20070259052A1 (en) * | 2006-05-05 | 2007-11-08 | Shire International Licensing B.V. | Assay for lanthanum hydroxycarbonate |
ATE530896T1 (de) * | 2006-05-05 | 2011-11-15 | Shire Int Licensing Bv | Assay für lanthan-hydroxycarbonat |
CN101077338B (zh) * | 2006-05-24 | 2012-06-20 | 天津大学 | 纳米碳酸镧口腔崩解片及制备方法 |
GB0714670D0 (en) | 2007-07-27 | 2007-09-05 | Ineos Healthcare Ltd | Use |
GB0720220D0 (en) * | 2007-10-16 | 2007-11-28 | Ineos Healthcare Ltd | Compound |
US8974824B2 (en) * | 2008-03-26 | 2015-03-10 | Mylan Laboratories Ltd. | Lanthanum composition |
WO2010085520A1 (en) * | 2009-01-21 | 2010-07-29 | Mylan Inc. | Disintegrable formulations of lanthanum carbonate |
WO2010106557A2 (en) * | 2009-03-20 | 2010-09-23 | Panacea Biotec Limited | Stable pharmaceutical formulations comprising anhydrous lanthanum carbonate and process for preparation thereof |
US20120058200A1 (en) * | 2009-05-15 | 2012-03-08 | Natco Pharma Limited | Process for the preparation of lanthanum carbonate dihydrate |
GB0913525D0 (en) | 2009-08-03 | 2009-09-16 | Ineos Healthcare Ltd | Method |
GB201001779D0 (en) | 2010-02-04 | 2010-03-24 | Ineos Healthcare Ltd | Composition |
CN103037870B (zh) * | 2010-05-12 | 2016-05-25 | 斯派克托姆制药公司 | 碱式碳酸镧、碳酸氧镧及其制造方法和用途 |
EP2441436A1 (de) * | 2010-10-13 | 2012-04-18 | Fresenius Medical Care Deutschland GmbH | Phosphatbinderformulierung zur einfachen Einnahme |
US8263119B2 (en) | 2010-12-01 | 2012-09-11 | Shire Llc | Capsule formulations containing lanthanum compounds |
US8697132B2 (en) | 2010-12-01 | 2014-04-15 | Shire Llc | Capsule and powder formulations containing lanthanum compounds |
WO2012098562A2 (en) | 2011-01-19 | 2012-07-26 | Panacea Biotec Limited | Liquid oral compositions of lanthanum salts |
CN102432055B (zh) * | 2011-09-23 | 2013-10-16 | 北京大学 | 用于治疗高磷血症的碳酸镧纳米颗粒、其制备方法及用途 |
CN102442692B (zh) * | 2011-09-23 | 2014-08-27 | 北京大学 | 碳酸镧水合物的制备方法 |
EA021712B1 (ru) * | 2012-06-12 | 2015-08-31 | Общество С Ограниченной Ответственностью "Рубикон" | Противовоспалительное средство для лечения контактного дерматита |
CN103251648B (zh) | 2013-05-15 | 2015-08-05 | 乔敏 | 治疗血磷酸盐过多症及缺铁性贫血症的铁基蒙脱石药物及其制备方法 |
JP6225270B2 (ja) * | 2014-10-02 | 2017-11-01 | 東和薬品株式会社 | 粒度調整された炭酸ランタン水和物からなる医薬 |
CN104473963B (zh) * | 2014-12-24 | 2017-10-10 | 厦门科明达科技有限公司 | 稀土化学药碳酸镧咀嚼片的制备方法 |
US10058569B2 (en) * | 2015-06-24 | 2018-08-28 | Lupin Limited | Lanthanum carbonate compositions |
CN105125575B (zh) * | 2015-08-07 | 2018-06-08 | 康臣药业(内蒙古)有限责任公司 | 一种治疗高磷酸盐血症药物的制备方法 |
ES2848476T3 (es) | 2015-11-30 | 2021-08-09 | Toray Industries | Columna de adsorción de fibra porosa y fósforo |
CN107876000A (zh) * | 2017-10-30 | 2018-04-06 | 浙江大学 | 一种纳米除磷剂、制备方法及应用 |
CN110579499A (zh) * | 2018-06-08 | 2019-12-17 | 北京华睿鼎信科技有限公司 | 一种碳酸镧或其制剂中碱式碳酸镧杂质的检定方法 |
MX2021004516A (es) * | 2018-10-26 | 2021-06-15 | Sumitomo Chemical Co | Metodo para produccion de hidrato de carbonato de lantano. |
CN111620363A (zh) * | 2020-06-13 | 2020-09-04 | 南京卡文迪许生物工程技术有限公司 | 一种四水合碳酸镧的制备方法及其产品 |
WO2022014122A1 (ja) | 2020-07-13 | 2022-01-20 | 恒隆 川口 | セリウム化合物を有効成分として含む、医薬組成物 |
CN114477265B (zh) * | 2020-11-13 | 2023-11-03 | 南京正济医药研究有限公司 | 一种四水碳酸镧的制备方法 |
CN115849429B (zh) * | 2023-01-06 | 2024-01-23 | 湖南明瑞制药股份有限公司 | 一种小粒径四水碳酸镧的制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06705B2 (ja) * | 1985-12-19 | 1994-01-05 | 旭化成工業株式会社 | リン酸イオンの固定化剤 |
-
1995
- 1995-03-25 GB GBGB9506126.3A patent/GB9506126D0/en active Pending
-
1996
- 1996-03-19 TR TR97/01030T patent/TR199701030T1/xx unknown
- 1996-03-19 DK DK96905960T patent/DK0817639T3/da active
- 1996-03-19 EA EA199700266A patent/EA000270B1/ru not_active IP Right Cessation
- 1996-03-19 HU HU9900799A patent/HU224198B1/hu active IP Right Grant
- 1996-03-19 US US08/913,960 patent/US5968976A/en not_active Expired - Lifetime
- 1996-03-19 JP JP52904096A patent/JP3224544B2/ja not_active Expired - Lifetime
- 1996-03-19 BR BR9607926A patent/BR9607926A/pt not_active IP Right Cessation
- 1996-03-19 DE DE69617659A patent/DE69617659D1/de not_active Expired - Lifetime
- 1996-03-19 CZ CZ19973017A patent/CZ293494B6/cs not_active IP Right Cessation
- 1996-03-19 CA CA002216437A patent/CA2216437C/en not_active Expired - Lifetime
- 1996-03-19 CN CN96193918A patent/CN1102393C/zh not_active Expired - Lifetime
- 1996-03-19 AT AT96905960T patent/ATE209923T1/de active
- 1996-03-19 KR KR1019970706684A patent/KR100329340B1/ko not_active IP Right Cessation
- 1996-03-19 EP EP96905960A patent/EP0817639B1/en not_active Expired - Lifetime
- 1996-03-19 DE DE69617659T patent/DE69617659T4/de not_active Expired - Lifetime
- 1996-03-19 NZ NZ303260A patent/NZ303260A/xx not_active IP Right Cessation
- 1996-03-19 ES ES96905960T patent/ES2170223T3/es not_active Expired - Lifetime
- 1996-03-19 PT PT96905960T patent/PT817639E/pt unknown
- 1996-03-19 PL PL96322450A patent/PL184315B1/pl unknown
- 1996-03-19 EE EE9700325A patent/EE04096B1/xx unknown
- 1996-03-19 SK SK1288-97A patent/SK282607B6/sk not_active IP Right Cessation
- 1996-03-19 DE DE1996617659 patent/DE122007000022I1/de active Pending
- 1996-03-19 WO PCT/GB1996/000575 patent/WO1996030029A1/en active IP Right Grant
- 1996-03-19 AU AU49514/96A patent/AU702073B2/en not_active Ceased
- 1996-03-19 DE DE122007000022C patent/DE122007000022I2/de active Active
- 1996-03-20 TW TW085103365A patent/TW436288B/zh not_active IP Right Cessation
- 1996-03-25 ZA ZA962369A patent/ZA962369B/xx unknown
-
1997
- 1997-09-24 NO NO19974425A patent/NO313488B1/no not_active IP Right Cessation
- 1997-09-25 MX MX9707334A patent/MX9707334A/es unknown
-
1998
- 1998-07-14 HK HK98109160A patent/HK1008182A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP9900799A2 (hu) | Eljárás lantán-karbonát-hidrátok előállítására és az azokat tartalmazó gyógyászati készítmények | |
HUP9701416A2 (hu) | Fenilszubsztituált alkenilkarbonsav-guanididek, eljárás azok előállítására, alkalmazásuk és az azokat tartalmazó gyógyszerkészítmények | |
GB1465442A (en) | Method of manufacturing carboxymethyl cellulose | |
TR199802039T2 (xx) | Yeni alfa-hidroksilik asit t�revleri, �retimleri ve kullan�mlar�. | |
ES476919A1 (es) | Procedimiento para la preparacion de nuevos compuestos de 2-pirrolidona. | |
GB1436487A (en) | Compositions for oral hygiene | |
ES460664A1 (es) | Un metodo de preparar una sal de cerio de sulfadiazina. | |
GB1489400A (en) | Aluminium hydroxycarbonate hydrate | |
GB1488444A (en) | Process for producing aluminium chloro-hydroxides | |
ES412423A1 (es) | Procedimiento para la produccion de clerohidroxides de alu-minio. | |
JPS5780340A (en) | Preparation of basic aluminum lactate | |
GB2006201A (en) | Production of nitroguanidine from guanidine nitrate and nitric acid | |
GB1439907A (en) | Process for the purification of lithium hexafluoroarsenate | |
IE40245B1 (en) | Aluminium hydroxychlorides | |
ES2072191A1 (es) | Prodecimiento de obtencion de hidroxicloruro de zinc,zn5 (oh)8 cl2.h20y su uso como corrector de zinc. | |
JPS554349A (en) | Preparation of creatine | |
WO1989009766A3 (en) | Process for the preparation of 2,4,6-triiodo-5-amino-n-alkylisophthalamic acid | |
IE45984L (en) | Manufacture of aluminium ethylphosphite | |
GB1462728A (en) | Process for producing hydroxy-aluminum nitrate polymer | |
SU502862A1 (ru) | Способ получени пропиленхлоргидрина | |
HUP0000199A2 (hu) | Eljárás nagytisztaságú kaptopril előállítására | |
SU643504A2 (ru) | Способ получени координационных соединений силиконатов щелочных металлов | |
JPS55125164A (en) | Coating pigment and production thereof | |
ES436472A2 (es) | Procedimiento para la produccion de clorohidroxidos de alu- minio. | |
GR81060B (en) | Lorazepam-containing sleeping pill |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HFG4 | Patent granted, date of granting |
Effective date: 20050420 |
|
GB9A | Succession in title |
Owner name: SHIRE INTERNATIONAL LICENSING B.V., NL Free format text: FORMER OWNER(S): ANORMED CORPORATION, CA; ANORMED INC., CA; JOHNSON MATTHEY PUBLIC LIMITED COMPANY, GB |